ATE525081T1 - Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit - Google Patents

Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit

Info

Publication number
ATE525081T1
ATE525081T1 AT03711550T AT03711550T ATE525081T1 AT E525081 T1 ATE525081 T1 AT E525081T1 AT 03711550 T AT03711550 T AT 03711550T AT 03711550 T AT03711550 T AT 03711550T AT E525081 T1 ATE525081 T1 AT E525081T1
Authority
AT
Austria
Prior art keywords
upa
tpa
urokinase
peptides
regulating
Prior art date
Application number
AT03711550T
Other languages
English (en)
Inventor
Abd-Al-Roof Higazi
Original Assignee
Thrombotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/020077 external-priority patent/WO2003006042A1/en
Application filed by Thrombotech Ltd filed Critical Thrombotech Ltd
Application granted granted Critical
Publication of ATE525081T1 publication Critical patent/ATE525081T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT03711550T 2002-05-08 2003-03-12 Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit ATE525081T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/063,046 US20030211095A1 (en) 2002-05-08 2002-05-08 Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
PCT/US2002/020077 WO2003006042A1 (en) 2001-07-10 2002-06-24 Peptide for regulation of tissue plasminogen activator
PCT/US2003/007683 WO2003095476A2 (en) 2002-05-08 2003-03-12 PEPTIDES FOR REGULATION OF UROKINASE (uPA) AND TISSUE TYPE (tPA) PLASMINOGEN ACTIVATOR AND METHOD OF OPTIMIZING THERAPEUTIC EFFICACY

Publications (1)

Publication Number Publication Date
ATE525081T1 true ATE525081T1 (de) 2011-10-15

Family

ID=29399060

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03711550T ATE525081T1 (de) 2002-05-08 2003-03-12 Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit

Country Status (10)

Country Link
US (1) US20030211095A1 (de)
EP (1) EP1507547B1 (de)
JP (1) JP2006502096A (de)
AT (1) ATE525081T1 (de)
AU (1) AU2003213856B2 (de)
CA (1) CA2488968C (de)
DK (1) DK1507547T3 (de)
ES (1) ES2373713T3 (de)
IL (1) IL165066A (de)
WO (1) WO2003095476A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003297477A1 (en) * 2002-12-31 2004-07-29 The General Hospital Corporation Methods and compositions for protection against thrombolysis-associated reperfusion injury
WO2009013753A1 (en) * 2007-07-24 2009-01-29 Thrombotech Ltd. Peptides derived from plasminogen activator inhibitor-1 and uses thereof
BRPI0906867A2 (pt) 2008-01-09 2019-09-24 Intrexon Corp inibidores terapêuticos da função pai-1 e métodos de uso dos mesmo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558010A (en) * 1980-04-03 1985-12-10 Abbott Laboratories Recombinant deoxyribonucleic acid which codes for plasminogen activator and method of making plasminogen activator protein therefrom
CA1338839C (en) * 1988-01-29 1997-01-14 Yoshio Sasaki Controlled release formulation
US5130143A (en) * 1988-11-04 1992-07-14 The Research Foundation Of State University Of New York Use of a low affinity-heparin fraction in conjunction with t-pa for thrombolytic therapy
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US6150332A (en) * 1997-01-09 2000-11-21 Virginia Commonwealth University Method and composition for lowering low density lipoprotein cholesterol
CA2306953A1 (en) * 1997-10-17 1999-04-29 Abd Al-Roof Higazi Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
EP1414479A4 (de) * 2001-07-10 2005-07-13 Thrombotech Ltd Peptid zur regulierung des gewebeplasminogenaktivators

Also Published As

Publication number Publication date
DK1507547T3 (da) 2012-01-16
ES2373713T3 (es) 2012-02-08
AU2003213856A1 (en) 2003-11-11
EP1507547B1 (de) 2011-09-21
IL165066A0 (en) 2005-12-18
EP1507547A4 (de) 2007-03-14
AU2003213856B2 (en) 2008-10-16
CA2488968C (en) 2013-10-29
WO2003095476A2 (en) 2003-11-20
WO2003095476A3 (en) 2004-04-01
JP2006502096A (ja) 2006-01-19
CA2488968A1 (en) 2003-11-20
IL165066A (en) 2011-03-31
EP1507547A2 (de) 2005-02-23
US20030211095A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
Cubellis et al. Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1.
DeClerck et al. Inhibition of autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase inhibitor MI/TIMP-2
Bode The structure of thrombin: a janus-headed proteinase
ATE182336T1 (de) Peptidinhibitoren der urokinaserezeptor-aktivität
PT1178958E (pt) N-cianometilamidas como inibidores de proteases
ES2031826T3 (es) Procedimiento para producir nuevos peptidos activadores del plasminogeno.
PL377553A1 (pl) Peptydy oraz pokrewne cząsteczki modulujące aktywność czynnika wzrostu nerwów
DK0770139T3 (da) En svamp, hvor areA-genet er blevet modificeret, samt et areA-gen fra aspergillus oryzae
ATE301198T1 (de) Phospahatasen mit verbesserter phytase-aktivität
ES8800347A1 (es) Metodo para preparar uroquinasa de una sola cadena resistente a proteasas
CA2563675A1 (en) Recombinantly modified plasmin
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
DE60306934D1 (de) Verwendung von Nitrilenverbindungen als Arztneimittel
Wiederanders The function of propeptide domains of cysteine proteinases
ATE525081T1 (de) Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit
EP0290118A3 (de) Fibrinolytisch wirksames Enzym
Stack et al. Modulation of tissue plasminogen activator-catalyzed plasminogen activation by synthetic peptides derived from the amino-terminal heparin binding domain of fibronectin.
DE59206628D1 (en) Expression signalpeptid-freier staphylokinasen
Arza et al. Prostromelysin‐1 (proMMP‐3) stimulates plasminogen activation by tissue‐type plasminogen activator
DK0672150T3 (da) Modificeret Kluyveromyces-gær, fremstilling og anvendelse
ATE226591T1 (de) Oligopeptide hergeleitet von fragmenten des c- reaktiven proteins
WO2003053999A3 (de) Selektive arylguanidinpeptide als urokinaseinhibitoren
Paoni et al. Involvement of residues 296–299 in the enzymatic activity of tissue-type plasminogen activator
ATE194360T1 (de) Verfahren und mittel für die herstellung von bindungsproteinen für inhibitoren von plasmaproteinasen
DE59608327D1 (de) Verwendung von plasminogenaktivatoren zum lokalen knochenaufbau

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1507547

Country of ref document: EP